EPRS1 and prostate cancer: Although no direct link between halofuginone-mediated inhibition of EPRS1 and cancer cell growth has been established to date, the action of halofuginone in reducing breast and prostate cancer bone metastases in mice (by inhibiting TGF-β/bone morphogenetic protein signaling) suggests the possibility that EPRS1 contributes to the underlying process101.